|1.||“Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed or Refractory Multiple Myeloma” – Abstract # 53188 Sunday, December 9, 2012, 6:00 PM-8:00 PM, Hall B1-B2, Level 1, Building B (Georgia World Congress Center)|
|John A Lust, MD, PhD 1, Saad Z Usmani, MD FACP 2, Mehdi Hamadani, MD 3, Charles Barranco 4*, Martha Q Lacy, MD 1, Angela Dispenzieri, MD 1, Morie A Gertz 1, David Dingli, M.D., Ph.D. 1, Stephen Russell, MD, PhD 1*, Francis K Buadi, M.D. 1, Steven R Zeldenrust, MD, PhD 1, Suzanne R Hayman, MD 1, S. Vincent Rajkumar, MD 1, Shaji K. Kumar, MD 1, John Thompson 5*, Catherine A Taylor 5* and Richard Dondero 6*|
|1Division of Hematology, Mayo Clinic, Rochester, MN, 2Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, 3Hematology/Oncology Bone Marrow Transplant, West Virginia University Hospitals, Inc., Morgantown, WV, 4Senesco Technologies, Inc., Bridgewater, NJ, 5Biology, University of Waterloo, Waterloo, ON, Canada, 6Senesco Technologies Inc., Bridgewater, NJ|
|2.||“Combination Therapy with Novel Nanoparticle, SNS01-T, and Lenalidomide Triggers Synergistic Cytotoxicity in Vitro and in Vivo in Multiple Myeloma and Mantle Cell Lymphoma” – Abstract # 51240 Monday, December 10, 2012, 6:00 PM-8:00 PM, Hall B1-B2, Level 1, Building B (Georgia World Congress Center)|
|Catherine A Taylor 1, Terence Tang 1, Zhongda Liu 1, Sarah Francis 1, Zheng Qifa 1, Richard Dondero 2 and John Thompson 1,2|
|1Biology, University of Waterloo, Waterloo, ON, Canada 2Senesco Technologies Inc., Bridgewater, NJ|
Senesco To Present On SNS01-T At 54th American Society Of Hematology Annual Meeting
Check Out Our Best Services for Investors
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.